

Phase I trial MM-402-101

Submission date 14/05/2024	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 21/05/2024	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 13/01/2026	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Public, Scientific, Principal investigator

Contact name

Dr David Gregory

Contact details

11 Tiger Court
Kings Drive Prescot
Liverpool
United Kingdom
L34 1BH
+44 (0)1514824700
davidgregory@macplc.com

Type(s)

Scientific

Contact name

None Jo Brady

Contact details

Senior Consultant
DLRC Regulatory Consultancy
Suite 201, The Nexus Building, Broadway
Letchworth Garden City
United Kingdom

Herts SG6 3TA
+44 01462 372472
Jo.Brady@dlrcgroup.com

Additional identifiers

Integrated Research Application System (IRAS)
1007767

Study information

Scientific Title

Phase I trial MM-402-101 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 24/10/2023, Wales Research Ethics Committee 1 (Health and Care Research Wales, Castlebridge 4, 15-19 Cowbridge Road, Cardiff, CF11 9AB, United Kingdom; +44 (0)2922940912; wales.rec1@wales.nhs.uk), ref: 23/WA/0135 and CTA 57953/0002/001-0001

Study design

Phase I study in 40 healthy volunteers

Primary study design

Interventional

Study type(s)

Safety, Other

Health condition(s) or problem(s) studied

Healthy volunteers

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

14/10/2024

Eligibility**Key inclusion criteria**

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Total final enrolment

0

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

10/05/2024

Date of final enrolment

30/09/2024

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MAC Clinical Research Liverpool

11 Tiger Court
King's Business Park
Liverpool
England
L34 1BH

Study participating centre

MAC Clinical Research Manchester

Citylabs 1.0
Nelson St
Manchester
England
M13 9NQ

Sponsor information

Organisation

Mind Medicine Inc.

Funder(s)

Funder type

Industry

Funder Name

Mind Medicine Inc.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available